Demyelinating Diseases: Clinical Trials

2185 completed, 552 unknown, 461 recruiting, 281 terminated. 1388 Not applicable, 596 Phase 2, 391 Phase 3, 357 Phase 1, 233 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	1388	Completed 749, Unknown 251, Recruiting 166, Not yet recruiting 77, Active not recruiting 58, Terminated 45, Withdrawn 20, Enrolling by invitation 19, Suspended 3
Phase 2	596	Completed 317, Terminated 84, Recruiting 57, Unknown 49, Withdrawn 36, Active not recruiting 24, Not yet recruiting 22, Enrolling by invitation 5, Suspended 2
Phase 3	391	Completed 230, Terminated 50, Active not recruiting 32, Recruiting 32, Unknown 24, Withdrawn 13, Not yet recruiting 8, Enrolling by invitation 1, Suspended 1
Phase 1	357	Completed 193, Recruiting 41, Terminated 39, Unknown 30, Withdrawn 18, Not yet recruiting 16, Active not recruiting 14, Enrolling by invitation 3, Suspended 3
Phase 4	233	Completed 135, Terminated 36, Unknown 22, Withdrawn 13, Active not recruiting 11, Recruiting 11, Not yet recruiting 3, Enrolling by invitation 2
Early Phase 1	43	Completed 15, Recruiting 8, Not yet recruiting 6, Unknown 5, Withdrawn 5, Suspended 2, Active not recruiting 1, Terminated 1

Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis Body-weight supported treadmill training in a room cooled to 16°C - Multiple Sclerosis, Neurological Rehabilitation	Not applicable	Withdrawn	Memorial University of Newfoundland		2030-01-01	2024-11-27
Inductive Therapeutic Exercise in Multiple Sclerosis Experimental: Inductive Therapeutic Exercise (ETI), Control: Sham Inductive Therapeutic Exercise (sham-ETI) - Multiple Sclerosis	Not applicable	Not yet recruiting	Fundación San Juan De Dios	30	2027-10-01	2026-10-02
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)	Not applicable	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-01	2026-09-01
Exploring Reproductive Decision-Making Among Women With Multiple Sclerosis Multiple Sclerosis		Not yet recruiting	Assiut University	272	2027-06-01	2026-09-21
IT and IV Lentiviral Gene Therapy for X-ALD Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy	Not applicable	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-01	2026-09-01
Direct Lentiviral Injection Gene Therapy for MLD Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)	Not applicable	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-05-31	2026-09-01
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive	Phase 2	Not yet recruiting	Moein Amin	20	2027-03-01	2026-08-19
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis	Phase 1 / Phase 2	Not yet recruiting	AbelZeta Inc.	119	2027-02-01	2026-10-13
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy UPLIZNA - Neuromyelitis Optica Spectrum Disorder, Pregnancy Related		Recruiting	Amgen	60	2027-01-15	2026-10-29
Exercise With and Without Cognitive Training Effect of Exercise with and Without Cognitive Training on Gait - Multiple Sclerosis	Not applicable	Not yet recruiting	VA Office of Research and Development	30	2027-01-04	2026-03-03
Efficacy of Seated Physical Activity INtervention(SPIN) for Wheelchair Users With Multiple Sclerosis SPIN exercise-training, Control Condition (WELL) - Multiple Sclerosis	Not applicable	Not yet recruiting	The University of Texas Health Science Center, Houston	100	2027-01-04	2026-10-23
Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia Investigational Combination Product - Periventricular Leukomalacia, White Matter Disease	Early Phase 1	Withdrawn	MGAM LLC		2027-01-01	2025-07-22
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle	Phase 2	Withdrawn	Michael, Levy M.D.,Ph.D.		2026-12-31	2025-07-16
Lead Exposure and Multiple Sclerosis Multiple Sclerosis		Not yet recruiting	Assiut University	140	2026-12-30	2026-02-20
Local Vibration and Ankle Mobilization in Multiple Sclerosis Local Vibration, Ankle Joint Mobilization - Multiple Sclerosis	Not applicable	Not yet recruiting	Gaziantep Islam Science and Technology University	60	2026-12-15	2026-10-19
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)	Phase 1	Not yet recruiting	Imviva Bio	81	2026-12-01	2026-08-24
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care Cohort - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive		Not yet recruiting	Luxembourg Institute of Health	100	2026-12-01	2026-09-22
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder	Phase 1 / Phase 2	Not yet recruiting	Tianjin Medical University General Hospital	20	2026-12-01	2026-10-16
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease	Phase 2	Not yet recruiting	Polaryx Therapeutics, Inc.	24	2026-12-01	2026-07-31
Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis Autologous haemopoietic stem cell transplantation - Multiple Sclerosis	Not applicable	Not yet recruiting	Tianjin Medical University General Hospital	20	2026-12-01	2026-10-16

Showing 20 of 4056. Sign in to see all of them.

Narrower conditions

Multiple Sclerosis (3154)  ·  Multiple Sclerosis, Relapsing-Remitting (614)  ·  Multiple Sclerosis, Chronic Progressive (243)  ·  Fatigue (211)  ·  Motor Activity (174)  ·  Neuromyelitis Optica (172)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (136)  ·  Stroke (109)  ·  Parkinson Disease (98)  ·  Guillain-Barre Syndrome (95)  ·  Autoimmune Diseases (78)  ·  Muscle Spasticity (78)  ·  Cognitive Dysfunction (75)  ·  Spinal Cord Injuries (73)

Broader conditions

Nervous System Diseases (3989)  ·  Immune System Diseases (3890)  ·  Autoimmune Diseases of the Nervous System (3846)  ·  Autoimmune Diseases (3821)  ·  Demyelinating Autoimmune Diseases, CNS (3670)  ·  Pathological Conditions, Signs and Symptoms (1183)  ·  Pathologic Processes (683)  ·  Disease Attributes (597)  ·  Signs and Symptoms (570)  ·  Chronic Disease (507)  ·  Central Nervous System Diseases (486)  ·  Brain Diseases (412)  ·  Multiple Sclerosis (401)  ·  Neurologic Manifestations (350)

Interventions

Interferon beta-1a (107)  ·  ocrelizumab (82)  ·  Exercise (72)  ·  Dimethyl Fumarate (70)  ·  Natalizumab (67)  ·  Interferon beta-1b (64)  ·  Fingolimod Hydrochloride (58)  ·  Glatiramer Acetate (55)  ·  Rituximab (43)  ·  Blood Specimen Collection (40)  ·  Methylprednisolone (40)  ·  teriflunomide (40)  ·  Alemtuzumab (35)  ·  4-Aminopyridine (34)  ·  ofatumumab (33)

Sponsors

Biogen (165)  ·  Novartis Pharmaceuticals (94)  ·  Merck KGaA, Darmstadt, Germany (49)  ·  Bayer (47)  ·  Assiut University (42)  ·  Hoffmann-La Roche (40)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (36)  ·  Sanofi (35)  ·  Hasselt University (34)  ·  Assistance Publique - Hôpitaux de Paris (33)  ·  Johns Hopkins University (33)  ·  Kessler Foundation (32)  ·  Fondazione Don Carlo Gnocchi ETS (30)  ·  University of Washington (28)  ·  Gazi University (27)

Countries

United States (1490)  ·  France (497)  ·  Italy (384)  ·  Germany (372)  ·  Turkey (Türkiye) (341)  ·  United Kingdom (333)  ·  Canada (321)  ·  Spain (299)  ·  Poland (206)  ·  Belgium (199)  ·  Czechia (181)  ·  Switzerland (168)  ·  Denmark (150)  ·  Netherlands (146)  ·  China (140)

Top investigators

Daniel S Reich, M.D. (11)  ·  Cagla Ozkul (9)  ·  Michael Levy, MD, PhD (9)  ·  Peter Feys, prof. dr. (9)

Results publications

PMID 31072380, PMID 21387374, PMID 33023488, PMID 32447743, PMID 34882037, PMID 42578463, PMID 23669008, PMID 25475413, PMID 27411694, PMID 27733070, PMID 29275977, PMID 30918100, PMID 31654272, PMID 31762387, PMID 32710396, PMID 36163349, PMID 37652990, PMID 37745914, PMID 39935588, PMID 40258203, PMID 40756531, PMID 40966534, PMID 42328798, PMID 6685237, PMID 12525714, PMID 21586746, PMID 22622860, PMID 23531349, PMID 24131282, PMID 25245812, PMID 26932146, PMID 28002679, PMID 28002688, PMID 28825348, PMID 30144037, PMID 31675266, PMID 32426039, PMID 32539719, PMID 33332761, PMID 33414927, PMID 34035833, PMID 34376508, PMID 34378446, PMID 35003076, PMID 36619856, PMID 37272540, PMID 39251561, PMID 39383458, PMID 40743487, PMID 42368888

NIH funding

2023 (26), 2014 (22), 2015 (21), 2018 (19), 2019 (18), 2016 (16), 2017 (15), 2009 (13), 2008 (12), 2025 (11), 2005 (6), 2004 (3), K23AT004433 (2), K24AT012644 (2), P30DK056336 (2)